Drug Trial Radar · NCT07397949
Rebamipide Versus Diquafosol for Perioperative Dry Eye in Cataract Surgery
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
May 11, 2026
Primary completion
Dec 2026
Study completion Mar 2027
Sponsor
- Lead sponsor
- Samsung Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is designed to compare two commonly used eye drop treatments for dry eye disease in patients undergoing cataract surgery. Dry eye disease is common in people who need cataract surgery and may worsen before or after surgery, causing eye discomfort, blurred vision, and unstable vision. Proper management of dry eye before and after surgery may help improve eye comfort and the accuracy of vision outcomes. In this study, patients with mild to moderate dry eye disease who are scheduled for cataract surgery will be randomly assigned to receive one of two treatments: Rebamipide eye drops, or Diquafosol eye drops Participants will begin using the assigned eye drops one month before cataract surgery and continue treatment for three months after surgery. The eye drops will be used only in the eye undergoing surgery. Researchers will examine whether one treatment is as effective as the other in improving tear film stability and reducing dry eye symptoms around the time of cataract surgery. Eye examinations and questionnaires will be performed before surgery, on the day of surgery, and during follow-up visits after surgery. The information gained from this study may help doctors choose the most appropriate treatment for managing dry eye disease in patients undergoing cataract surgery.
Conditions
- Dry Eye Disease (DED)
- Cataract
Interventions
Rebamipide 2% ophthalmic solutionDrug
Topical administration to the surgical eye, four times daily.
Diquafosol 3% ophthalmic solutionDrug
Topical administration to the surgical eye, four times daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Tear Film Breakup Time (TBUT)Time frame: From baseline to postoperative 1 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Samsung Mec
Seoul, Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.